Own and execute a fast-moving rare/ultra-rare disease US launch with cross-functional Brand and Therapeutic Liaison alignment, while maintaining long-term asset strategy and patient-first impact.

• Marketing and TLL integration: lead end-to-end pre-launch and launch strategy and execution in the US.
• Brand and patient strategy: define differentiated brand direction in a small patient population with complex pathways.
• Cross-functional alignment: drive coordinated planning with Medical, Market Access, Sales, and Global teams to execute launches.
• Patient-centric execution: connect patient journeys, diagnostic barriers, and treatment access to decisions.
• Executive visibility: provide data-driven insights and recommendations to Executive Leadership.
• Talent and culture: attract, coach, and retain talent and push a culture of ownership and speed.
• Forecast and scenario planning: contribute to market planning, forecasting, and strategy under uncertainty.
• Risk/opportunity management: rapidly identify risks and adjust strategy accordingly.
• KOL and advocacy engagement: build partnerships with leaders and centers of excellence.
• Asset lifecycle planning: develop launch readiness, annual plans, and medium-term optimization strategies.